GlassScriptPhysician profile
Justin Mahon
NPI 1073992962
$2,295.74
in general payments reported to CMS, 2019-2025
25 companies · $654 in 2025
The $654 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $55.90 · 2021: $159 · 2022: $91.24 · 2023: $655 · 2024: $553 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.28 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.47 | 2021-2025 | |
| Lilly USA, LLC | $363.21 | 2020-2025 | Jardiance, Emgality, Zepbound |
| Pfizer INC. | $237.25 | 2023-2025 | |
| Revance Therapeutics, INC. | $196.83 | 2025 | Daxi, Daxxify |
| Phathom Pharmaceuticals, INC. | $143.45 | 2024-2025 | Voquezna |
| Abbott Laboratories | $137.84 | 2023-2025 | Freestyle Libre 3, Id Now Instrument |
| Astellas Pharma US INC | $128.28 | 2023 | Veozah |
| Roche Diagnostics Corporation | $127.00 | 2019 | |
| Glaxosmithkline, LLC. | $99.77 | 2022-2024 | Shingrix, Arexvy, Bexsero |
| Otsuka America Pharmaceutical, INC. | $70.22 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $57.88 | 2023-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $55.63 | 2023 | |
| Corcept Therapeutics | $47.99 | 2025 | Korlym |
| Alk-Abello, INC | $34.11 | 2025 | Odactra, Ragwitek, Grastek |
| Janssen Pharmaceuticals, INC | $30.50 | 2024 | Xarelto |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $25.39 | 2025 | |
| Genentech USA, INC. | $25.19 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.68 | 2023 | Jardiance |
| Exact Sciences Corporation | $20.99 | 2025 | The Cologuard Plus Collection Kit |
| Kaleo, INC. | $18.75 | 2023 | Auvi-Q |
| Tris Pharma INC | $17.54 | 2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $16.80 | 2023 | Quviviq |
| Tolmar, INC. | $15.21 | 2023 | |
| Amneal Pharmaceuticals LLC | $13.63 | 2021 | |
| Phadia US INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Mahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.